Dharma R Thapa1, Shehnaz K Hussain, Wen-Ching Tran, Gypsyamber Dʼsouza, Jay H Bream, Chad J Achenback, Velpandi Ayyavoo, Roger Detels, Otoniel Martínez-Maza. 1. *University of California, Los Angeles, AIDS Institute, Los Angeles, CA; Departments of †Obstetrics and Gynecology; ‡Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA; §Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA; ‖Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, CA; Departments of ¶Epidemiology; #Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; **Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; and ††Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA.
Abstract
OBJECTIVE: To determine if changes in levels of serum microRNAs (miRNAs) were seen preceding the diagnosis of AIDS-related non-Hodgkin lymphoma (AIDS-NHL). DESIGN: Serum miRNA levels were compared in 3 subject groups from the Multicenter AIDS Cohort Study: HIV-negative men (n = 43), HIV-positive men who did not develop NHL (n = 45), and HIV-positive men before AIDS-NHL diagnosis (n = 62, median time before diagnosis, 8.8 months). METHODS: A total of 175 serum-enriched miRNAs were initially screened to identify differentially expressed miRNAs among these groups and the results validated by quantitative polymerase chain reaction. Receiver-operating characteristic analysis was then performed to assess biomarker utility. RESULTS: Higher levels of miR-21 and miR-122, and a lower level of miR-223, were able to discriminate HIV-infected from the HIV-uninfected groups, suggesting that these miRNAs are biomarkers for HIV infection but are not AIDS-NHL specific. Among the HIV-infected groups, a higher level of miR-222 was able to discriminate diffuse large B-cell lymphoma (DLBCL) and primary central nervous system lymphoma (PCNSL) subjects from HIV-infected subjects who did not develop NHL, with area under the receiver-operating characteristic curve of 0.777 and 0.792, respectively. At miR-222 cutoff values of 0.105 for DLBCL and 0.109 for PCNSL, the sensitivity and specificity were 75% and 77%, and 80% and 82%, respectively. CONCLUSIONS: Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals. Higher serum level of miR-222 has clear potential as a serum biomarker for earlier detection of DLBCL and PCNSL among HIV-infected individuals.
OBJECTIVE: To determine if changes in levels of serum microRNAs (miRNAs) were seen preceding the diagnosis of AIDS-related non-Hodgkin lymphoma (AIDS-NHL). DESIGN: Serum miRNA levels were compared in 3 subject groups from the Multicenter AIDS Cohort Study: HIV-negative men (n = 43), HIV-positive men who did not develop NHL (n = 45), and HIV-positive men before AIDS-NHL diagnosis (n = 62, median time before diagnosis, 8.8 months). METHODS: A total of 175 serum-enriched miRNAs were initially screened to identify differentially expressed miRNAs among these groups and the results validated by quantitative polymerase chain reaction. Receiver-operating characteristic analysis was then performed to assess biomarker utility. RESULTS: Higher levels of miR-21 and miR-122, and a lower level of miR-223, were able to discriminate HIV-infected from the HIV-uninfected groups, suggesting that these miRNAs are biomarkers for HIV infection but are not AIDS-NHL specific. Among the HIV-infected groups, a higher level of miR-222 was able to discriminate diffuse large B-cell lymphoma (DLBCL) and primary central nervous system lymphoma (PCNSL) subjects from HIV-infected subjects who did not develop NHL, with area under the receiver-operating characteristic curve of 0.777 and 0.792, respectively. At miR-222 cutoff values of 0.105 for DLBCL and 0.109 for PCNSL, the sensitivity and specificity were 75% and 77%, and 80% and 82%, respectively. CONCLUSIONS: Altered serum levels of miR-21, miR-122, and miR-223 are seen in HIV-infected individuals. Higher serum level of miR-222 has clear potential as a serum biomarker for earlier detection of DLBCL and PCNSL among HIV-infected individuals.
Authors: Lorena Di Lisio; Nerea Martinez; Santiago Montes-Moreno; Miguel Piris-Villaespesa; Margarita Sanchez-Beato; Miguel A Piris Journal: Blood Date: 2012-07-03 Impact factor: 22.113
Authors: Santiago Montes-Moreno; Nerea Martinez; Beatriz Sanchez-Espiridión; Ramon Díaz Uriarte; Maria Elena Rodriguez; Anabel Saez; Carlos Montalbán; Gonzalo Gomez; David G Pisano; Juan Fernando García; Eulogio Conde; Eva Gonzalez-Barca; Andres Lopez; Manuela Mollejo; Carlos Grande; Miguel Angel Martinez; Cherie Dunphy; Eric D Hsi; Gabrielle B Rocque; Julie Chang; Ronald S Go; Carlo Visco; Zijun Xu-Monette; Ken H Young; Miguel A Piris Journal: Blood Date: 2011-06-01 Impact factor: 22.113
Authors: Rachel E Culpin; Stephen J Proctor; Brian Angus; Stephen Crosier; John J Anderson; Tryfonia Mainou-Fowler Journal: Int J Oncol Date: 2010-08 Impact factor: 5.650
Authors: Raquel Malumbres; Kristopher A Sarosiek; Elena Cubedo; Jose W Ruiz; Xiaoyu Jiang; Randy D Gascoyne; Robert Tibshirani; Izidore S Lossos Journal: Blood Date: 2008-12-01 Impact factor: 22.113
Authors: Cheng Li; Sang-Woo Kim; Deepak Rai; Aswani R Bolla; Siddharth Adhvaryu; Marsha C Kinney; Ryan S Robetorye; Ricardo C T Aguiar Journal: Blood Date: 2009-03-10 Impact factor: 22.113
Authors: Anja Roehle; Kai P Hoefig; Dirk Repsilber; Christoph Thorns; Marita Ziepert; Kai O Wesche; Marlen Thiere; Markus Loeffler; Wolfram Klapper; Michael Pfreundschuh; András Matolcsy; Heinz-Wolfram Bernd; Lila Reiniger; Hartmut Merz; Alfred C Feller Journal: Br J Haematol Date: 2008-06-03 Impact factor: 6.998
Authors: Victoria N Parikh; Joseph Park; Ivana Nikolic; Richard Channick; Paul B Yu; Teresa De Marco; Priscilla Y Hsue; Stephen Y Chan Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: Rui Zhang; Bo Pang; Tao Xin; Hua Guo; Yi Xing; Shangchen Xu; Bin Feng; Bin Liu; Qi Pang Journal: Mol Neurobiol Date: 2015-01-31 Impact factor: 5.590
Authors: Erin C Peckham-Gregory; Dharma R Thapa; Jeremy Martinson; Priya Duggal; Sudhir Penugonda; Jay H Bream; Po-Yin Chang; Sugandha Dandekar; Shen-Chih Chang; Roger Detels; Otoniel Martínez-Maza; Zuo-Feng Zhang; Shehnaz K Hussain Journal: Cancer Epidemiol Date: 2016-10-01 Impact factor: 2.984
Authors: Daniel D Murray; Kazuo Suzuki; Matthew Law; Jonel Trebicka; Jacquie Neuhaus; Deborah Wentworth; Margaret Johnson; Michael J Vjecha; Anthony D Kelleher; Sean Emery Journal: PLoS One Date: 2015-10-14 Impact factor: 3.240